Memorial Sloan Kettering Cancer Center

Next generation trials for MRD

Ola Landgren, M.D., Ph.D.
Chief of Myeloma Service, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College, New York

New York, June 24, 2016

Memorial Sloan Kettering Cancer Center

1. MRD as a prognostic marker

1. MRD as a prognostic marker



1. MRD as a prognostic marker

- Early/late MRD
- MRD in relation to tumor biology
- MRD in relation to given therapy

2. MRD as a regulatory surrogate endpoint

2. MRD as a regulatory surrogate endpoint



2. MRD as a regulatory surrogate endpoint

- White paper
- Meta analysis
- Prospective trials

3. MRD-driven clinical trials

3. MRD-driven clinical trials

3. MRD-driven clinical trials

- Duration of combination therapy
- Determine use of delayed vs upfront HDM-ASCT
- Pre-biochemical relapse (MRD conversion)

Our next generation studies

Proposed MRD-driven treatment paradigm for newly dx myeloma pts



Footnote: Modern combination therapy: e.g., carfilzomib, lenalidomide, and dexamethasone (reference: (8)); maintenance therapy: e.g., lenalidomide

Landgren and Giralt. *Bone Marrow Transplantation 2016*

Longitudinal MRD testing



MRD 10^{-6}

- Ensure maintained MRD 10^{-6} negativity
- Dissect mechanisms of MRD positivity, develop targets

- Develop strategies when MRD 10^{-6} negativity → positivity

Landgren et al. *unpublished data*

Memorial Sloan Kettering Cancer Center

Modern combination therapy → rapid, deep and sustained MRD-


Memorial Sloan Kettering
Cancer Center
1884
Quality
of life
2016. 2. 29

Thank you for your attention!

Ola Landgren, M.D, Ph.D.
Professor of Medicine
Chief, Myeloma Service
Memorial Sloan-Kettering Cancer Center
1275 York Avenue, New York, NY 10065, USA
Email: landgrec@mskcc.org
Phone: 212-639-5126